Nightingale Health Plc, Press release, 31 January 2024 at 8:00 a.m. (EET)

Nightingale Health Plc ("Nightingale Health"), a pioneer in health risk detection and preventative health, has received five new patents from the Finnish Patent and Registration Office. Nightingale Health announced during 2023 that it had received nine patents, and with these five new patents the company's patent portfolio expands to cover additional health areas such as infectious diseases and anemia.

The first of the newly received patents was granted for the company's proprietary technology's ability to determine whether an individual is at risk of developing a musculoskeletal and/or connective tissue disease such as osteoarthritis. The second patent was granted for the ability to determine whether an individual is at risk of developing an infectious disease or a complication thereof. The third patent was granted for the ability to determine whether an individual is at risk of developing anemia. The fourth and fifth patents were granted for the ability to determine whether an individual is at risk of developing a metabolic condition related to nutritional state or fluid balance. Understanding and managing these conditions is important for maintaining health and preventing chronic diseases.

The patents increase the value of the company's intellectual property assets. In addition to the patents granted in Finland, the company has several international patent applications pending.

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it's also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 25 countries in the healthcare and medical research sectors. The company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 450 peer-reviewed publications validate the technology. The company's Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com